ArticleFrontiers in medicine2026
Assessing the risk of adverse drug events from combining aromatase inhibitors with CDK4/6 inhibitors using the FAERS and JADER databases.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reports of adverse drug events (ADEs) involving aromatase inhibitors (AIs) and cyclin-dependent kinase 4/6 (CDK4/6) inhibitors exist, but a comprehensive assessment of their combined safety in real-world practice has not been conducted. Methods: The U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the Japanese Adverse Drug Event Report (JADER) database were used to collect data from the first quarter of 2015 to the third quarter of 2025. Disproportionality analysis was performed to identify ADEs associated with combination therapy. Multivariate logistic regression was used to explore factors associated with designated serious outcomes. Results: A total of 28,495 reports related to combination therapy were included in FAERS. Disproportionality analysis identified 150 ADEs. The three most frequently reported ADEs were fatigue, neutropenia, and white blood cell count decreased. Signals not mentioned in drug labels were found, like skin hypopigmentation, vertigo positional, and plicated tongue. Combination therapy showed stronger reporting signals for some ADEs, including neutropenia, anaemia, and leukopenia. Among 1,186 reports in the JADER database, we identified 25 positive signals, including neutropenia, alanine aminotransferase increased, and aspartate aminotransferase increased. Multivariate logistic regression showed that body weight was associated with the occurrence of serious outcomes and hematological toxicity. Conclusion: This study not only identified key signals that align with earlier clinical trials but also detected several ADEs not listed in drug labeling. Concurrently, combination therapy was associated with stronger disproportionality signals for certain specific ADEs compared with monotherapy. The findings provided clinicians crucial insights and emphasized the importance of additional research centered on causality to verify the outcomes observed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.